AU2021280328A1 - Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis - Google Patents

Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis Download PDF

Info

Publication number
AU2021280328A1
AU2021280328A1 AU2021280328A AU2021280328A AU2021280328A1 AU 2021280328 A1 AU2021280328 A1 AU 2021280328A1 AU 2021280328 A AU2021280328 A AU 2021280328A AU 2021280328 A AU2021280328 A AU 2021280328A AU 2021280328 A1 AU2021280328 A1 AU 2021280328A1
Authority
AU
Australia
Prior art keywords
amino acids
free amino
present
pharmaceutical formulation
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021280328A
Other languages
English (en)
Inventor
Damiano ANGOLI
Stephen J. Gatto
Astrid GROSCHE
Sadasivan Vidyasagar
Xiaodong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Amilyfe LLC
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Amilyfe LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc, Amilyfe LLC filed Critical University of Florida
Publication of AU2021280328A1 publication Critical patent/AU2021280328A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021280328A 2020-05-29 2021-05-28 Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis Pending AU2021280328A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063032185P 2020-05-29 2020-05-29
US63/032,185 2020-05-29
US202063080470P 2020-09-18 2020-09-18
US63/080,470 2020-09-18
US202063088813P 2020-10-07 2020-10-07
US63/088,813 2020-10-07
US202163136404P 2021-01-12 2021-01-12
US63/136,404 2021-01-12
PCT/US2021/034807 WO2021243183A1 (en) 2020-05-29 2021-05-28 Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis

Publications (1)

Publication Number Publication Date
AU2021280328A1 true AU2021280328A1 (en) 2022-11-17

Family

ID=78722883

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021280328A Pending AU2021280328A1 (en) 2020-05-29 2021-05-28 Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis

Country Status (10)

Country Link
US (1) US20230201151A1 (https=)
EP (1) EP4157218A4 (https=)
JP (1) JP2023531872A (https=)
KR (1) KR20230018474A (https=)
CN (1) CN115697301A (https=)
AU (1) AU2021280328A1 (https=)
BR (1) BR112022024033A2 (https=)
CA (1) CA3177780A1 (https=)
MX (1) MX2022015044A (https=)
WO (1) WO2021243183A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116036277B (zh) * 2022-07-19 2023-10-31 广州国家实验室 氯离子在预防、治疗冠状病毒所致疾病中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
CN104207146A (zh) * 2014-07-26 2014-12-17 胡安然 呼吸系统疾病全营养配方食品
EP3691628A1 (en) * 2017-10-02 2020-08-12 University of Florida Research Foundation, Incorporated Materials and methods for inhibiting tumor growth
WO2019070759A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
CA3116015A1 (en) * 2018-10-30 2020-05-07 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating cystic fibrosis

Also Published As

Publication number Publication date
KR20230018474A (ko) 2023-02-07
BR112022024033A2 (pt) 2022-12-20
US20230201151A1 (en) 2023-06-29
WO2021243183A8 (en) 2022-01-13
WO2021243183A1 (en) 2021-12-02
MX2022015044A (es) 2023-01-04
CN115697301A (zh) 2023-02-03
EP4157218A4 (en) 2024-06-26
JP2023531872A (ja) 2023-07-26
EP4157218A1 (en) 2023-04-05
CA3177780A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
RU2524304C2 (ru) Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций
CA3075271C (en) Methods of using dipivefrin
JP7359519B2 (ja) ライノウイルス感染症の予防又は治療のための薬物
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
US20230058134A1 (en) Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
CN115515560A (zh) 冠状病毒感染的治疗
AU2016287580A1 (en) Compositions and methods for the treatment of viral infection
US20230201151A1 (en) Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
JP2023524693A (ja) ラクトフェリンの投与によるＳＡＲＳ－ＣｏＶ－２ウイルス侵入の阻害およびその使用
EP1437134A1 (en) Anti-influenza drugs
JP7527288B2 (ja) 急性増悪をポリクローナル免疫グロブリンで予防または治療するための方法および組成物
CN115443126A (zh) 用于预防或治疗SARS-CoV-2感染的相容性溶质
US11197912B2 (en) Prevention and treatment of viral infection and viral infection-induced organ failure
CN115279357B (zh) 含有羟基脲的抑制炎症反应的药物组合物
EP4166136A1 (en) Inhalable protease inhibitors for use in the prevention and/or treatment of fibrotic autoimmune or inflammatory lung diseases
JP2003155230A (ja) 抗インフルエンザ薬
EP3906934B1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
US20220016160A1 (en) Method for preventing or treating infection of respiratory virus utilizing gold nanoparticles
EP4710930A1 (en) Anti-influenza virus composition containing xanthan gum or fucoidan
Heida Inhalation of antiviral drugs to combat respiratory virus infections: broadening the horizon in times of pandemic pressure
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
WO2014199486A1 (ja) 嚥下障害改善用医薬品

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO AMILYFE, LLC AND UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.